Selected article for: "second wave and study period"

Author: Armann, Jakob Peter; Kirsten, Carolin; Galow, Lukas; Kahre, Elisabeth; Haag, Luise; Dalpke, Alexander; Lück, Christian; Berner, Reinhard
Title: SARS-CoV-2 transmissions in students and teachers: seroprevalence follow-up study in a German secondary school in November and December 2020
  • Cord-id: o6du89fg
  • Document date: 2021_3_24
  • ID: o6du89fg
    Snippet: OBJECTIVE: To quantify the number of undetected SARS-CoV-2 infections in educational settings. DESIGN: Serial SARS-CoV-2 seroprevalence study before and during the second wave of the COVID-19 pandemic. SETTING: Secondary school in Dresden, Germany. PARTICIPANTS: Grade 8–12 students and their teachers were invited to participate in serial blood sampling and SARS-CoV-2 IgG antibody assessment. MAIN OUTCOME MEASURE: Seroprevalence of SARS-CoV-2 antibodies in study population. RESULTS: 247 student
    Document: OBJECTIVE: To quantify the number of undetected SARS-CoV-2 infections in educational settings. DESIGN: Serial SARS-CoV-2 seroprevalence study before and during the second wave of the COVID-19 pandemic. SETTING: Secondary school in Dresden, Germany. PARTICIPANTS: Grade 8–12 students and their teachers were invited to participate in serial blood sampling and SARS-CoV-2 IgG antibody assessment. MAIN OUTCOME MEASURE: Seroprevalence of SARS-CoV-2 antibodies in study population. RESULTS: 247 students and 55 teachers participated in the initial study visit and 197 students and 40 teachers completed follow-up. Seroprevalence increased from 1.7% (0.3–3.3) to 6.8% (3.8–10.1) during the study period mirroring the increase of officially reported SARS-CoV-2 infections during this time. The ratio of undetected to detected SARS-CoV-2 infections ranged from 0.25 to 0.33. CONCLUSIONS: We could not find evidence of relevant silent, asymptomatic spread of SARS-CoV-2 in schools neither in a low prevalence setting nor during the second wave of the pandemic, making it unlikely that educational settings play a crucial role in driving the SARS-CoV-2 pandemic. TRIAL REGISTRATION NUMBER: DRKS00022455.

    Search related documents:
    Co phrase search for related documents
    • additional serological test and low prevalence: 1
    • additional serological test and low prevalence setting: 1
    • adolescent child and longitudinal study: 1, 2, 3
    • lockdown measure and longitudinal study: 1
    • longitudinal study and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • longitudinal study and low prevalence setting: 1, 2
    • longitudinal study and low proportion: 1, 2, 3, 4